Treatment of High-Risk Prostate Cancer Guided by Novel Diagnostic Radio- and Molecular Tracers
- Status
- RECRUITING
- Phase
- PHASE2/PHASE3
Clinical Trials Related to Darolutamide
Related studies linked through entity extraction aliases.
SNV1521 in Participants With Advanced Solid Tumors
- Status
- RECRUITING
- Phase
- PHASE1
Gedatolisib in Combination With Darolutamide in Metastatic Castration-Resistant Prostate Cancer
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Abiraterone and Prednisone or Darolutamide for the Treatment of Advanced Prostate Cancer
- Status
- RECRUITING
- Phase
- PHASE2
Study to Test the Drug Darolutamide Along With the Drugs Leuprolide Acetate and Exemestane in Patients With Recurrent Ovarian Granulosa Cell Tumors
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents
- Status
- RECRUITING
- Phase
- PHASE3
Abemaciclib Plus Darolutamide in Prostate Cancer That Has Spread After Initial Treatment
- Status
- COMPLETED
- Phase
- PHASE1
A Study to Investigate the Biological Effects of Saruparib (AZD5305), Darolutamide, and in Combination in Men With Newly Diagnosed Prostate Cancer.
- Status
- RECRUITING
- Phase
- PHASE1
A Study of Pasritamig (JNJ-78278343) in Combination With Other Agents for Metastatic Prostate Cancer
- Status
- RECRUITING
- Phase
- PHASE1
Darolutamide With Radium-223 or Placebo and the Effect on Radiological Progression-Free Survival for Patients With mCSPC
- Status
- WITHDRAWN
- Phase
- PHASE3
Docetaxel or Cabazitaxel With or Without Darolutamide in mCRPC
- Status
- RECRUITING
- Phase
- PHASE2
Darolutamide in Patients With Androgen Receptor-Positive Salivary Gland Carcinoma (DISCOVARY)
- Status
- COMPLETED
- Phase
- PHASE2
Testing the Anti-cancer Drug Darolutamide in Patients With Testosterone-Driven Salivary Gland Cancers
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Neo-DAB: Darolutamide and Abemaciclib in Prostate Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)
- Status
- RECRUITING
- Phase
- PHASE1
Study of AZD5305 When Given in Combination With New Hormonal Agents in Patients With Metastatic Prostate Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
TT-702 in Patients With Advanced Solid Tumours.
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score, The Guidance Trial
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Psma Intensity Can be Altered by Androgen and Phospho-SrC Obstruction
- Status
- COMPLETED
- Phase
- PHASE2
Neoadjuvant Androgen Deprivation, Darolutamide, and Ipatasertib in Men With Localized, High Risk Prostate Cancer
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2